[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,337
  • Shares Outstanding, K 124,498
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -63,060 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.97
  • Price/Sales 106.30
  • Price/Cash Flow N/A
  • Price/Book 4.38

Options Overview Details

View History
  • Implied Volatility 276.21% (+51.84%)
  • Historical Volatility 42.91%
  • IV Percentile 82%
  • IV Rank 34.68%
  • IV High 652.40% on 03/30/26
  • IV Low 76.52% on 05/15/26
  • Expected Move (DTE 11) 0.0425 (3.22%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 290
  • Volume Avg (30-Day) 479
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 20,395
  • Open Int (30-Day) 34,508
  • Expected Range 1.2775 to 1.3625

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 3
  • High Estimate $-0.17
  • Low Estimate $-0.19
  • Prior Year $-0.20
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +10.00%
on 06/25/26
1.4200 -7.04%
on 06/17/26
+0.0900 (+7.32%)
since 06/05/26
3-Month
1.2000 +10.00%
on 06/25/26
2.3400 -43.59%
on 04/16/26
-0.2000 (-13.16%)
since 04/06/26
52-Week
1.0000 +32.00%
on 03/30/26
3.0600 -56.86%
on 12/12/25
-0.6200 (-31.96%)
since 07/03/25

Most Recent Stories

More News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.3200 (unch)
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...

ACOG : 7.90 (+0.13%)
ONCT : 0.5266 (-24.11%)
CBAY : 32.48 (+0.03%)
MIST : 1.3200 (unch)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals: Q1 Earnings Snapshot

Milestone Pharmaceuticals: Q1 Earnings Snapshot

MIST : 1.3200 (unch)
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

CARDAMYST™ (etripamil) nasal spray launch for PSVT is  gaining traction ; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative...

MIST : 1.3200 (unch)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity...

MIST : 1.3200 (unch)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.3967
2nd Resistance Point 1.3733
1st Resistance Point 1.3467
Last Price 1.3200
1st Support Level 1.2967
2nd Support Level 1.2733
3rd Support Level 1.2467

See More

52-Week High 3.0600
Fibonacci 61.8% 2.2731
Fibonacci 50% 2.0300
Fibonacci 38.2% 1.7869
Last Price 1.3200
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.